Advancements by the biopharmaceutical sector have radically altered the trajectory of HIV/AIDS. What once was a death sentence is now a manageable chronic condition for millions of Americans. Powerful new therapies and improved access to care are helping millions to live longer, fuller and more productive lives.

Since 1995, the death rate for HIV/AIDS patients has fallen 85%.

860,000 lives have been saved by advances in HIV/AIDS pharmaceutical treatments. Life expectancy for patients is at an all time high. A 20-year-old diagnosed today can live a full life with treatment.

Consider Patient A and Patient B

<table>
<thead>
<tr>
<th>PATIENT A</th>
<th>PATIENT B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosed in 1983</td>
<td>Diagnosed in 1991</td>
</tr>
<tr>
<td>Lack of Treatments</td>
<td>Numerous Treatments Available</td>
</tr>
<tr>
<td>Died 1993</td>
<td>Turned 56 in 2015</td>
</tr>
<tr>
<td>Died 10 years after treatment</td>
<td>24 years after diagnosis, still active</td>
</tr>
</tbody>
</table>

In the last 25 years, HIV fell from the 7th to the 23rd leading cause of death in the U.S.

Hospitalization rates have fallen nearly 70% since 1995. Less time in the hospital means more time with friends and family.
IN THE LAST 20 YEARS ALONE, 500 years of life have been added per 100,000 patients thanks to HIV/AIDS treatments. In that time you could ...

Threats to Progress?
But this progress is being threatened. Between 2014–2015, the number of HIV/AIDS drugs placed on the specialty tier by insurance companies increased from 20% to 30%.

Healthy patients lead to a healthy economy. Better treatments keep patients in the workforce and added $615 billion to the economy between 1996–2012.

Given the medical benefits to patients and savings to our healthcare system, HIV/AIDS patients should not have to face barriers in accessing the therapies most appropriate for them.


- Fly to the moon 60,833 times.
- Cruise across the Atlantic 26,071 times.
- Orbit the earth in the Space Station 2.8 million times.